Clinical Trials Browser

Breast Neoplasms, Breast Neoplasms, Male

NCT07455110 2026-03-27

BR Male

Completed

65 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT06422455 2026-03-18

Access to Genetic Testing in Underserved Patients With Cancer

Phase NA Recruiting

800 enrolled

BreastGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT03384914 2026-03-06

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

Phase 2 Active not recruiting

119 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual, Breast Neoplasms, Male

NCT00897702 2026-01-28

Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer

Completed

269 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT05501704 2026-01-07

ETHAN - ET for Male BC

Phase 2 Recruiting

60 enrolled

Breast

Breast Neoplasms, Male

NCT02950259 2025-12-03

Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)

Phase 1 Completed

16 enrolled 10 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT00295893 2025-09-25

Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer

Phase 2 Active not recruiting

121 enrolled 10 charts

Breast

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT00609791 2025-06-19

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer

Phase 2 Active not recruiting

40 enrolled 16 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT01938833 2025-05-16

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer

Phase 1/2 Terminated

9 enrolled 7 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

Clinical Trials

HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer

BR Male

Access to Genetic Testing in Underserved Patients With Cancer

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer

ETHAN - ET for Male BC

Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)

Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer